Constance A Benson1, Janet W Andersen2, Bernard J C Macatangay3, Robbie B Mailliard3, Charles R Rinaldo3, Sarah Read4, Dawn R Bozzolo5, Lynette Purdue6, Cheryl Jennings7, Michael C Keefer8, Marshall Glesby9, Pablo Tebas10, Amy Falk Russell11, Jason Martin12, Paula Annunziato11, Zoran Popmihajlov11, Jeffrey L Lennox13. 1. Division of Infectious Diseases, University of California, San Diego. 2. Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts. 3. Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pennsylvania. 4. Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH), Rockville. 5. Social and Scientific Systems, Inc, Silver Spring. 6. Pharmaceutical Affairs Branch, Division of AIDS, NIAID/NIH, Rockville, Maryland. 7. Clinical Retrovirology Research Laboratory, Rush University, Chicago, Illinois. 8. Division of Infectious Diseases, University of Rochester, New York, New York. 9. Division of Infectious Diseases, Weill Cornell Medical College, Cornell University, New York, New York. 10. Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia. 11. Clinical Research, Merck Research Laboratories, Merck & Co, Inc, Kenilworth, New Jersey. 12. Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co, Inc, Kenilworth, New Jersey. 13. Division of Infectious Diseases, Emory University, Atlanta, Georgia.
Abstract
Background: Herpes zoster (HZ) risk is increased in human immunodeficiency virus (HIV)-infected persons. Live attenuated zoster vaccine (ZV) reduces HZ incidence and severity in adults; safety and immunogenicity data in HIV-infected adults are limited. Methods: We conducted a randomized, double-blind, placebo-controlled trial in HIV-infected adults virally suppressed on antiretroviral therapy (ART). Participants, stratified by CD4+ count (200-349 or ≥350 cells/µL), were randomized 3:1 to receive ZV or placebo on day 0 and week 6. The primary endpoint was serious adverse event or grade 3/4 signs/symptoms within 6 weeks after each dose. Immunogenicity (varicella zoster virus [VZV]-specific glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay responses) was assessed at 6 and 12 weeks postvaccination. Results: Of 395 participants (296 ZV vs 99 placebo), 84% were male, 47% white, 29% black, and 22% Hispanic; median age was 49 years. Safety endpoints occurred in 15 ZV and 2 placebo recipients (5.1% [95% confidence interval {CI}, 2.9%-8.2%] vs 2.1% [95% CI, .3%-7.3%]; P = .26). Injection site reactions occurred in 42% of ZV (95% CI, 36.3%-47.9%) vs 12.4% of placebo recipients (95% CI, 6.6%-20.6%) (P < .001). Week 12 median natural log VZV antibody titer was higher for ZV (6.30 [Q1, Q3, 5.64, 6.96]) vs placebo (5.48 [Q1, Q3, 4.63, 6.44]; P < .001) overall and in the high CD4+ stratum (P = .003). VZV antibody titers were similar after 1 or 2 ZV doses. Polymerase chain reaction-confirmed HZ occurred in 2 participants (1 ZV; 1 placebo); none was vaccine strain related. Conclusions: Two doses of ZV in HIV-infected adults suppressed on ART with CD4+ counts ≥200 cells/µL were safe and immunogenic. Clinical Trials Registration: NCT00851786.
RCT Entities:
Background: Herpes zoster (HZ) risk is increased in human immunodeficiency virus (HIV)-infectedpersons. Live attenuated zoster vaccine (ZV) reduces HZ incidence and severity in adults; safety and immunogenicity data in HIV-infected adults are limited. Methods: We conducted a randomized, double-blind, placebo-controlled trial in HIV-infected adults virally suppressed on antiretroviral therapy (ART). Participants, stratified by CD4+ count (200-349 or ≥350 cells/µL), were randomized 3:1 to receive ZV or placebo on day 0 and week 6. The primary endpoint was serious adverse event or grade 3/4 signs/symptoms within 6 weeks after each dose. Immunogenicity (varicella zoster virus [VZV]-specific glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay responses) was assessed at 6 and 12 weeks postvaccination. Results: Of 395 participants (296 ZV vs 99 placebo), 84% were male, 47% white, 29% black, and 22% Hispanic; median age was 49 years. Safety endpoints occurred in 15 ZV and 2 placebo recipients (5.1% [95% confidence interval {CI}, 2.9%-8.2%] vs 2.1% [95% CI, .3%-7.3%]; P = .26). Injection site reactions occurred in 42% of ZV (95% CI, 36.3%-47.9%) vs 12.4% of placebo recipients (95% CI, 6.6%-20.6%) (P < .001). Week 12 median natural log VZV antibody titer was higher for ZV (6.30 [Q1, Q3, 5.64, 6.96]) vs placebo (5.48 [Q1, Q3, 4.63, 6.44]; P < .001) overall and in the high CD4+ stratum (P = .003). VZV antibody titers were similar after 1 or 2 ZV doses. Polymerase chain reaction-confirmed HZ occurred in 2 participants (1 ZV; 1 placebo); none was vaccine strain related. Conclusions: Two doses of ZV in HIV-infected adults suppressed on ART with CD4+ counts ≥200 cells/µL were safe and immunogenic. Clinical Trials Registration: NCT00851786.
Authors: Myron J Levin; Kenneth E Schmader; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman Journal: N Engl J Med Date: 2016-09-15 Impact factor: 91.245
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Laura Gilbert; Xun Wang; Robert Deiss; Jason Okulicz; Ryan Maves; Christina Schofield; Tomas Ferguson; Timothy Whitman; Karl Kronmann; Brian Agan; Anuradha Ganesan Journal: Clin Infect Dis Date: 2019-06-18 Impact factor: 9.079
Authors: Kristine M Erlandson; Amber Streifel; Alexander R Novin; Kellie L Hawkins; Clayton Foster; Jacob Langness; Mary Bessesen; Julian Falutz; Abeer Moanna; David Looney; Scott T Johns; Joseph B Nguyen; Michael N Oxman; Myron J Levin Journal: AIDS Res Hum Retroviruses Date: 2018-05-21 Impact factor: 2.205
Authors: Daniel J Grint; Helen I McDonald; Jemma L Walker; Gayatri Amirthalingam; Nick Andrews; Sara Thomas Journal: BMJ Open Date: 2020-01-29 Impact factor: 2.692